<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75808">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02118714</url>
  </required_header>
  <id_info>
    <org_study_id>M12-919</org_study_id>
    <secondary_id>2016-000722-19</secondary_id>
    <nct_id>NCT02118714</nct_id>
  </id_info>
  <brief_title>Atrasentan Spermatogenesis and Testicular Function</brief_title>
  <official_title>A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the effects of Atrasentan on sperm production and
      the function of the testicles in male subjects with Type 1 or 2 Diabetes and Nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who have a sperm concentration &lt; 15 million per mL</measure>
    <time_frame>Up to 26 weeks</time_frame>
    <description>Duplicate semen samples will be collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who enter the Observation Period and do not return to within 15% of Week 0 by 52 weeks after treatment discontinuation</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>Duplicate semen samples will be collected during the Observational Period. Sperm concentration will be calculated as measure of the number sperm per milliliter of semen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sperm motility</measure>
    <time_frame>From Week 0 to Week 26 and up to Week 52 after the end of treatment</time_frame>
    <description>Duplicate semen samples will be collected during the Treatment and Observation Periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum testosterone</measure>
    <time_frame>From Week 0 to Week 26 and up to Week 52 after the end of treatment</time_frame>
    <description>Serum hormones levels will be tested during the Treatment and Observational Periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estradiol</measure>
    <time_frame>From Week 0 to Week 26 and up to Week 52 after the end of treatment</time_frame>
    <description>Serum hormones levels will be tested during the Treatment and Observational Periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lutenizing Hormone (LH)</measure>
    <time_frame>From Week 0 to Week 26 and up to Week 52 after the end of treatment</time_frame>
    <description>Serum hormones levels will be tested during the Treatment and Observational Periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Follicle Stimulating Hormone (FSH)</measure>
    <time_frame>From Week 0 to Week 26 and up to Week 52 after the end of treatment</time_frame>
    <description>Serum hormones levels will be tested during the Treatment and Observational Periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inhibin B</measure>
    <time_frame>From Week 0 to Week 26 and up to Week 52 after the end of treatment</time_frame>
    <description>Serum hormones levels will be tested during the Treatment and Observational Periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sperm morphology</measure>
    <time_frame>From Week 0 to Week 26 and up to Week 52 after the end of treatment</time_frame>
    <description>Duplicate semen samples will be collected during the Treatment and Observational Periods. The percentage of sperm with normal versus abnormal morphology will be determined via microscopic analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in semen volume</measure>
    <time_frame>From Week 0 to Week 26 and up to Week 52 after the end of treatment</time_frame>
    <description>Duplicate semen samples will be collected during the Treatment and Observation Periods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sperm concentration</measure>
    <time_frame>From Week 0 to Week 26 and up to Week 52 after the end of treatment</time_frame>
    <description>Duplicate semen samples will be collected during the Treatment and Observational Periods. Sperm concentration will be calculated as measure of the number sperm per milliliter of semen.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nephropathy</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Atrasentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atrasentan daily (QD) for 26 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atrasentan</intervention_name>
    <description>Atrasentan</description>
    <arm_group_label>Atrasentan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males 30 to 75 years of age

          -  Type 1 or 2 diabetes and receiving treatment with at least one anti-hyperglycemic
             medication and angiotensin-converting enzyme inhibitors (ACEi)/angiotensin receptor
             blockers (ARB) (renin-angiotensin system [RAS] inhibitor)

          -  Estimated Glomerular Filtration Rate (eGFR) equal to or greater than 35 mL/min with
             the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Formula and Urine
             Albumin-to-Creatinine Ratio (UACR) equal to or greater than 30 and less than 5,000
             mg/g creatinine.

          -  Able to provide a semen specimen at the required intervals.

          -  Baseline sperm concentration equal to or greater than 30 million per mL.

        Exclusion Criteria:

          -  Treatment with hormone suppressive agents or cancer chemotherapy within the past 6
             months or planned during the study.

          -  History of severe peripheral edema or facial edema unrelated to trauma or history of
             myxedema in the prior 4 weeks prior to screening.

          -  History of pulmonary hypertension, pulmonary fibrosis or any lung disease requiring
             oxygen therapy.

          -  Documented diagnosis of heart failure, previous hospitalization for heart failure or
             current or constellation of symptoms (dyspnea on exertion, pedal edema, orthopnea,
             paroxysmal nocturnal dyspnea) felt to be compatible with heart failure, that was not
             explained by other causes, and for which there was a change in medication or other
             management directed at heart failure.

          -  Currently receiving or has received hormone replacement therapy within 6 months prior
             to screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa Wigderson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847-283-8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 125945</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 125945, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147794</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147794, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129010</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129010, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150989</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150989, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130308</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 130308, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 131068</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 131068, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124435</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 124435, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153176</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153176, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128919</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 128919, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 147795</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 147795, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124277</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 124277, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 153740</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 153740, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154264</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154264, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151692</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151692, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>April 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Diseases</keyword>
  <keyword>Urologic Diseases</keyword>
  <keyword>Diabetes Complications</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Diabetic Nephropathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrasentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
